Cantor Fitzgerald Reiterates Neutral Rating for Bristol-Myers Squibb (NYSE:BMY)
Cantor Fitzgerald reiterated their neutral rating on shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) in a research note published on Tuesday, MarketBeat.com reports. The brokerage currently has a $55.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Bristol-Myers Squibb’s FY2025 earnings at $6.81 EPS. BMY has been the subject […]
Cantor Fitzgerald reiterated their neutral rating on shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) in a research note published on Tuesday, MarketBeat.com reports. The brokerage currently has a $55.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Bristol-Myers Squibb’s FY2025 earnings at $6.81 EPS. BMY has been the subject […]
